These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Practical considerations in the treatment of ventricular arrhythmias with mexiletine.
    Author: Akhtar M.
    Journal: Am Heart J; 1984 May; 107(5 Pt 2):1086-90. PubMed ID: 6372424.
    Abstract:
    Mexiletine can be administered by intravenous, intramuscular, or oral route. However, the intramuscular route is seldom used because it offers no advantage over the other routes. Loading doses of about 400 mg may result in unacceptable side effects and are unnecessary for management of chronic ventricular arrhythmias. Therapeutic efficacy as well as side effects increase in proportion to increasing blood levels. At plasma levels of 2.0 mg/L, side effects are encountered in a significant number of patients. Because of its lack of serious toxicity even in patients with various systemic illnesses and its long elimination half-life, mexiletine should be considered as a first-line drug for treatment of ventricular arrhythmias.
    [Abstract] [Full Text] [Related] [New Search]